Entacapone as an adjunctive treatment to levodopa in Parkinson's disease
Development and Evaluation Committee
Record ID 32000008154
To summarise the available evidence on the use of entacapone as an adjunctive treatment to levodopa in Parkinson's disease.
Authors' recommendations: Entacapone has been shown to be effective in two relatively small published phase III randomised controlled trials. However, in one trial patients were less severely affected than those who would be treated in practice with the drug. There is no evidence on the ideal dose as phase III dose ranging studies have not been published and evidence for long-term effects is lacking. The results of three other randomised placebo controlled phase III trials are awaiting full publication, one of which has evaluated outcomes up to twelve months. Further appraisal of this therapy will be warranted at that time.
Authors' methods: Overview
Project Status: Completed
URL for project: http://www.wihrd.soton.ac.uk
Year Published: 1999
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Costs and Cost Analysis
- Parkinson Disease
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.